

# Non-Valvular Atrial Fibrillation

**Patient name**

## CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score <sup>1</sup>

Recommended by the European Society of Cardiology (ESC) and the South African Heart Association<sup>2</sup> as a means of assessing stroke risk in non-valvular atrial fibrillation (AF).<sup>1</sup>

**Risk Factors** **Score** *Tick those that are applicable*

Congestive Heart Failure	1	<input type="checkbox"/>
Hypertension	1	<input type="checkbox"/>
Age ≥ 75	2	<input type="checkbox"/>
Age 65-74	1	<input type="checkbox"/>
Diabetes Mellitus	1	<input type="checkbox"/>
Stroke/TIA/Thrombo-embolism	2	<input type="checkbox"/>
Vascular Disease	1	<input type="checkbox"/>
Sex Female	1	<input type="checkbox"/>
<b>TOTAL SCORE</b>		<input type="text"/>

# calculating STROKE risk

## Adjusted event rate according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>4</sup>

CHA <sub>2</sub> DS <sub>2</sub> -VASc score	Stroke and thromboembolism event rate at 1 year follow-up
0	1%
1	2%
2	4%
3	6%
4	9%
5	15%
6	20%
7	22%
8	22%
9	24%

Actual rates of stroke in contemporary cohorts may vary from these estimates.

*Based on their net clinical benefit.<sup>1</sup>*

## ESC recommendations for stroke prevention in patients with AF according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>1</sup>

CHA <sub>2</sub> DS <sub>2</sub> -VASc score	ESC recommendation	Evidence class & level
0*	No antiplatelet or anticoagulant treatment	IIIB
1	Oral anticoagulant should be considered. <b>Options: ‡</b> <ul style="list-style-type: none"> <li>• NOAC (preferred)</li> <li>• direct thrombin inhibitor [dabigatran], or</li> <li>• factor Xa inhibitor [e.g., rivaroxaban or apixaban]</li> <li>• VKA (INR target 2-3 with TTR ≥70%)</li> </ul>	IIaB
≥ 2	Oral anticoagulation is indicated. Assess for contraindications and correct reversible bleeding risk factors. <b>Options: ‡</b> <ul style="list-style-type: none"> <li>• NOAC (preferred)</li> <li>• direct thrombin inhibitor [dabigatran], or</li> <li>• factor Xa inhibitor [e.g., rivaroxaban or apixaban]</li> <li>• VKA (INR target 2-3 with TTR ≥70%)</li> </ul>	IA
	LAA occluding devices may be considered in patients with clear contraindications for oral anticoagulation	IIbC

AF: atrial fibrillation; INR: international normalised ratio; LAA: left atrial appendage; NOAC: non-vitamin K antagonist oral anticoagulant; TTR: time in therapeutic range; VKA: vitamin K antagonist \*Score of 0 includes women without other stroke factors

‡Treatment choice is made balancing the expected stroke reduction, bleeding risk and patient preference. When oral anticoagulation is initiated in a patient with AF who is eligible for a NOAC (apixaban, dabigatran or rivaroxaban), a NOAC is recommended in preference to a vitamin K antagonist.<sup>1</sup>

# Non-Valvular Atrial Fibrillation

## Patient name

## HAS-BLED score<sup>1</sup>

The HAS-BLED score allows clinicians to make an informed assessment of bleeding risk and prompts consideration of the correctable risk factors for bleeding.<sup>1</sup>

Clinical Characteristic	Score	Tick those that are applicable
Hypertension	1	<input type="checkbox"/>
Abnormal liver function	1	<input type="checkbox"/>
Abnormal renal function	1	<input type="checkbox"/>
Stroke	1	<input type="checkbox"/>
Bleeding history or predisposition	1	<input type="checkbox"/>
Labile INRs	1	<input type="checkbox"/>
Elderly (Age > 65)	1	<input type="checkbox"/>
Drugs	1	<input type="checkbox"/>
Alcohol	1	<input type="checkbox"/>
<b>TOTAL SCORE</b>		<input type="text"/>

## References

- Kirchhof P, Benussi S, Kotecha D, et al. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2016; 37(38): 2893-2962.
- Gopal R, Tayebjee MH. Perspectives on the modern management of non-valvular atrial fibrillation. *SA Heart* 2015; 12(2): 66-73.
- Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012; 33: 2719-2747. Corrigendum published in: *Eur Heart J* 2013; 34(36): 2850-2851
- Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; 138: 1093-1100.

# calculating BLEEDING risk

## Clinical risk estimation according to HAS-BLED score<sup>3</sup>

HAS-BLED score	Number of patients*	Number of bleeds*	Bleeds per 100 patient years*
0	798	9	1.13
1	1286	13	1.02
2	744	14	1.88
3	187	7	3.74
4	46	4	8.70
5	8	1	12.50
6	2	0	0
7	-	-	-
8	-	-	-
9	-	-	-

\* In patients with AF enrolled in the Euro Heart Survey

## HAS-BLED score – ESC recommendations<sup>3</sup>

- A HAS-BLED score  $\geq 3$  indicates that the patient is at "high risk".
- A high HAS-BLED score *per se* should not be used to exclude patients from oral anticoagulant therapy.
- In patients with a HAS-BLED score  $\geq 3$ , caution and regular review are recommended, as well as efforts to correct the potentially reversible risk factors for bleeding.

For full prescribing information, refer to the package insert approved by the Medicines Authority (SAHPRA).

[S4] XARELTO® 10: Each film-coated tablet contains rivaroxaban 10 mg. **South Africa:** [S4] Reg. No.: 42/8.2/1046; **Namibia:** [NS2] 10/8.2/0463. **Botswana:** BOT1302278; **Zimbabwe:** [PP10] Reg. 2017/10.2/5362; **Mauritius:** R12697/02/14

[S4] XARELTO® 15: Each film-coated tablet contains rivaroxaban 15 mg. **South Africa:** [S4] Reg. No.: 46/8.2/0111; **Namibia:** [NS2] 12/8.2/0006; [S2] **Botswana:** BOT1302296; **Zimbabwe:** [PP10] Reg. 2017/10.2/5363; **Mauritius:** R11772/02/14.

[S4] XARELTO® 20: Each film-coated tablet contains rivaroxaban 20 mg. **South Africa:** [S4] Reg. No.: 46/8.2/0112; **Namibia:** [NS2] 12/8.2/0007; [S2] **Botswana:** BOT1302297; **Zimbabwe:** [PP10] Reg. 2017/10.2/5364; **Mauritius:** R12698/02/14.

**HCR:** Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609.  
Tel: 011 921 5044 Fax: 011 921 5041

L.ZA.MKT.11.2018.2979

© Bayer November 2018